You are invited to attend this interactive educational program that is designed to provide busy clinicians with important information and practice tips regarding recent updates in the NCCN guidelines and a forum in which they can discuss cases, data, and best clinical practices with an expert on
You are invited to attend this interactive educational program that is designed to provide busy clinicians with important information and practice tips regarding recent updates in the NCCN guidelines and a forum in which they can discuss cases, data, and best clinical practices with an expert on
Routine monitoring of carcinoembryonic antigen (CEA) levels is standard in patients with resected colorectal cancer (CRC). The incidence of false-positives and the upper limits of false-positive elevations have not been previously well characterized.
Both 5-FU and oxaliplatin have been used as single agents in patients with colon cancer and severe liver dysfunction, but the combination of these drugs has not been yet investigated.
The 2013 NCCN Case Manager Webinar Series consists of six activities on the topics of Acute Lymphocytic Leukemia (ALL), Biomarkers, Colorectal Cancer, Metastatic Prostate Cancer, Multiple Myeloma, and Palliative Care.
The 2013 NCCN Clinical Practice Guidelines in Oncology address the evaluation and management of patients at risk of inherited susceptibility to colorectal cancer.
Colorectal cancer is a common and significant public health concern. The liver is the most common site of metastasis, and colorectal cancer liver metastases (CRLM) may affect up to 60% of patients at some time during the course of their disease.
This article reviews the various systemic therapy options for patients with metastatic colorectal cancer (CRC) that is judged to be noncurable. The choice of initial therapy depends on patient preferences, treatment goals, performance status, and presence of comorbid conditions.
Facebook
Twitter
LinkedIn
Forward